NCT00148642

Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)

Multi-center Clinical Trial of the Bard Silver-coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,003 (actual)
• Sponsor: C. R. Bard · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if the use of a silver-coated endotracheal tube (ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non silver-coated ETT in patients who have been mechanically ventilated for \>= 24 hours.

Detailed description

Nosocomial pneumonia is the leading cause of death from hospital-acquired infections.Ventilator associated pneumonia (VAP) develops in a significant percentage of patients who have been ventilated for at least 48 hours, and is associated with high morbidity, mortality,and financial costs. Silver is a well-characterized antimicrobial agent, and is the active agent in multiple medical products used to reduce or control infection. Bard has developed a proprietary antimicrobial ETT, manufactured with a hydrophilic coating containing a fine dispersion of silver salts. This study compare the incidence and time to onset of VAP in patients intubated for \>=24 hours with a proprietary silver-coated ETT versus those intubated for \>= 24 hours with a standard non-coated ETT.

Conditions

• Respiratory Failure

Interventions

Type	Name	Description
DEVICE	silver salts coated endotracheal tube	intubation with silver coated tube
DEVICE	uncoated endotracheal tube	intubation

Timeline

• Start date: 2002-11-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 2005-09-08
• Last updated: 2017-01-18

Locations

5 sites across 1 country: United States